A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study

Grant

Date/time Interval

  • January 4, 2019 - January 3, 2024

    • Awarded By

    Total Award Amount

  • 140100.00

    • Direct Costs

  • 107770.00

    • Sponsor Award Id

    • Contributor

  • Erica Stringer-Reasor M.D.   Investigator  
  • Gabrielle Rocque M.D.   Investigator